EMEA-002669-PIP02-20
Key facts
| Invented name |
Lorviqua
|
| Active substance |
Lorlatinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0006/2021
|
| PIP number |
EMEA-002669-PIP02-20
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of lung cancer
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pfizer Europa MA EEIG
Email: PIP_Enquiries@pfizer.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|